Merck shares slide as investors weigh kidney-cancer trial setback ahead of a near-term FDA decision

Merck & Co., Inc. (MRK) is down 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to lingering investor caution around Merck’s renal cell carcinoma (RCC) strategy after a late-stage first-line RCC study missed key endpoints, with some traders potentially de-risking ahead of an upcoming FDA action date for a separate Keytruda/Welireg filing. In the absence of a single, definitive headline today, this looks like a sentiment-driven pullback centered on oncology pipeline expectations.

Details:

Merck and partner Eisai disclosed that the Phase 3 LITESPARK-012 study in first-line advanced clear cell RCC did not meet its co-primary endpoints of progression-free survival and overall survival versus the established Keytruda + Lenvima regimen.

The LITESPARK-012 trial tested a triplet adding Welireg (belzutifan) to Keytruda (pembrolizumab) + Lenvima (lenvatinib), and also evaluated another combination arm that included investigational quavonlimab.

Merck has a June 19, 2026 FDA action date listed for a Keytruda + Welireg regulatory event, which can lead to position-sizing and volatility into the decision.

Separately, Merck recently highlighted FDA Breakthrough Therapy designation for investigational calderasib (MK-1084) in combination with Keytruda in certain first-line KRAS G12C-mutant NSCLC patients, which may not have been enough to offset near-term RCC disappointment.

Sources:

Merck, RTTNews, Merck

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRK Insider Trading Activity

$MRK insiders have traded $MRK stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:

JENNIFER ZACHARY (EVP, General Counsel) has made 0 purchases and 3 sales selling 121,573 shares for an estimated $14,485,690.
ROBERT M DAVIS (Chairman, CEO & President) has made 0 purchases and 2 sales selling 47,434 shares for an estimated $5,599,327.
CAROLINE LITCHFIELD (EVP & CFO) sold 41,997 shares for an estimated $5,023,311
CHIRFI GUINDO (Chief Marketing Officer) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $4,836,339.
RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) sold 37,685 shares for an estimated $4,557,024
JOHANNES JACOBUS OOSTHUIZEN (President, U.S. Market) sold 15,000 shares for an estimated $1,827,991
DEAN Y LI (Executive VP & President, MRL) sold 15,087 shares for an estimated $1,791,824
DALTON E. III SMART (SVP Fin. - Global Controller) has made 0 purchases and 2 sales selling 6,400 shares for an estimated $765,920.
DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) sold 5,000 shares for an estimated $609,525

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRK Hedge Fund Activity

We have seen 1,714 institutional investors add shares of $MRK stock to their portfolio, and 1,794 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CARDANO RISK MANAGEMENT B.V. removed 8,639,639 shares (-89.8%) from their portfolio in Q1 2026, for an estimated $1,037,836,634
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 7,007,793 shares (-70.5%) from their portfolio in Q1 2026, for an estimated $841,811,134
BLACKROCK, INC. added 6,734,865 shares (+3.1%) to their portfolio in Q1 2026, for an estimated $809,025,658
JPMORGAN CHASE & CO removed 6,001,669 shares (-17.0%) from their portfolio in Q4 2025, for an estimated $631,735,678
UBS GROUP AG removed 5,244,642 shares (-27.3%) from their portfolio in Q1 2026, for an estimated $630,012,620
PACER ADVISORS, INC. removed 5,237,153 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $551,262,724
MILLENNIUM MANAGEMENT LLC removed 4,829,660 shares (-71.0%) from their portfolio in Q1 2026, for an estimated $580,162,907

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRK Government Contracts

We have seen $6,595,521 of award payments to $MRK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ERVEBO PROCUREMENT: $2,843,515
VACCINE STORAGE AND ROTATION, 2021-2026: $1,267,628
WA COLUMBIA RIV FPO PIT TAGS URGENT: $499,552
OR-KLAMATH FALLS FWO-BIOMARK PURCH REQUE: $297,003
E14 IMPERIAL PONDS PIT SCANNER ARRAY: $127,600

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$MRK Congressional Stock Trading

Members of Congress have traded $MRK stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 02/04.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 12/19.
REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 12/18.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRK Analyst Ratings

Wall Street analysts have issued reports on $MRK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 12/15/2025

To track analyst ratings and price targets for $MRK, check out Quiver Quantitative's $MRK forecast page.

$MRK Price Targets

Multiple analysts have issued price targets for $MRK recently. We have seen 16 analysts offer price targets for $MRK in the last 6 months, with a median target of $132.5.

Here are some recent targets:

Geoff Meacham from Citigroup set a target price of $125.0 on 05/06/2026
Mohit Bansal from Wells Fargo set a target price of $145.0 on 05/01/2026
Michael Yee from UBS set a target price of $145.0 on 04/13/2026
Chris Schott from JP Morgan set a target price of $135.0 on 04/06/2026
Trung Huynh from RBC Capital set a target price of $142.0 on 03/30/2026
Emily Field from Barclays set a target price of $140.0 on 02/20/2026
Vamil Divan from Guggenheim set a target price of $140.0 on 02/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.